Search Within

Genitourinary Oncology Service

  1. "Martin Fleisher"
Formats
  1. Meeting Abstract (50)
  2. Journal Article (31)
Groups
  1. Department of Medicine (81)
  2. Solid Tumor Oncology Division (81)
  3. Epidemiology and Biostatistics (35)
  4. Biostatistics Service (32)
  5. GSK Faculty (25)
  6. Hematologic Malignancies, Division of (19)

More Groups

People
  1. Martin Fleisher (81)
  2. Howard Scher (78)
  3. Daniel Danila (48)
  4. Aseem Anand (33)
  5. Glenn Heller (30)
  6. Nicole Schreiber (17)

More People

Years
  1. 2020 (1)
  2. 2019 (1)
  3. 2018 (4)
  4. 2017 (4)
  5. 2016 (8)
  6. 2015 (6)

More Years

Publications
  1. Journal of Clinical Oncology (42)
  2. Cancer Research (6)
  3. Clinical Cancer Research (5)
  4. European Urology (4)
  5. Annals of Oncology (3)
  6. Clinical Chemistry (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (43)
  2. American Association for Cancer Research (12)
  3. Elsevier Science, Inc. (9)
  4. Oxford University Press (3)
  5. American Association for Clinical Chemistry (2)
  6. American Medical Association (2)

More Publishers

Results (81)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dickkopf-1 can lead to immune evasion in metastatic castration-resistant prostate cancer
    Journal Article

    Wise, D. R.; Schneider, J. A.; Armenia, J.; Febles, V. A.; McLaughlin, B.; Brennan, R.; Thoren, K. L.; Abida, W.; Sfanos, K. S.; De Marzo, A. M.; more...
    JCO Precision Oncology (2020)

    Fulltext@MSK | Save
  • Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer
    Meeting Abstract

    Scher, H. I.; McCormack, R. T.; Molina, A.; Smith, M. R.; Dreicer, R.; Saad, F.; De Wit, R.; Fizazi, K.; Aftab, D. T.; Limon, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Winquist, E.; McLaughlin, B.; Lu, D.; Orr, S.; Fleisher, M.; Lowes, L.; Anderson, A. K. L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Jayaram, A.; Winquist, E.; McLaughlin, B.; Lu, D.; Fleisher, M.; Orr, S.; Lowes, L.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Reply to C. Ren et al
    Journal Article

    Heller, G.; McCormack, R.; Kheoh, T.; Molina, A.; Smith, M. R.; Dreicer, R.; Saad, F.; de Wit, R.; Aftab, D. T.; Hirmand, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: A comparison with prostate-specific antigen across five randomized phase III clinical trials
    Journal Article

    Heller, G.; McCormack, R.; Kheoh, T.; Molina, A.; Smith, M. R.; Dreicer, R.; Saad, F.; de Wit, R.; Aftab, D. T.; Hirmand, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A)
    Meeting Abstract

    Scher, H. I.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R. P.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Changes in CTC burden and prevalence of specific CTC subtypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapuetics (Tx)
    Meeting Abstract

    Dittamore, R. V.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer
    Journal Article

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; McLaughlin, B.; Jendrisak, A.; Wang, Y.; Lee, J.; Greene, S.; Krupa, R.; Lu, D.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; McLaughlin, B.; Lu, D.; Louw, J.; Danila, D. C.; Dugan, L.; Johnson, A.; Heller, G.; more...
    European Urology (2017)

    Fulltext@MSK | Save